Ardea, headquartered in San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases. On June 19, 2012, Ardea was acquired by AstraZeneca PLC. Upon completion of the merger, Ardea became a wholly owned subsidiary of AstraZeneca. The total transaction value was approximately $1.26 billion. See Ardea's public filings with the Securities and Exchange Commission for more information.